Cost-effectiveness analysis of probiotic peanut oral immunotherapy (PPOIT) versus placebo in Australian children with peanut allergy alongside a randomised trial.

ABSTRACT:

Objective

To compared the cost-effectiveness of coadministration of a probiotic adjuvant with peanut oral immunotherapy (PPOIT) with placebo (no treatment) in children with peanut allergy.

Design

Prospectively planned cost-effectiveness analysis alongside a randomised control trial.

Setting

The Royal Children's Hospital, Melbourne, Australia.

Participants

56 children with peanut allergy aged 1-10 years at recruitment.

Intervention

A daily dose of probiotic Lactobacillus rhamnosus CGMCC 1.3724 (NCC4007) and peanut oral immunotherapy administered for 1.5 years.

Main outcomes measures

Costs were considered from a healthcare system perspective and included costs of treatment delivery and adverse events. Effectiveness outcomes included rate of s

SUBMITTER: Huang L 

PROVIDER: S-EPMC10729191 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature